France Becomes First in EU to Reimburse HOYA MiYOSMART Lenses

This decision reflects the power of collective advocacy across ophthalmologists, opticians, health professionals, health insurances and government stakeholders. It also positions France as a leader in championing children’s eye health across Europe.

From July 1, children in France aged 5 to 16 with high (-6.00D) and/or rapidly progressive (-0.50D/year) myopia will be eligible to receive MiYOSMART myopia control spectacle lenses through a reimbursement basis. MiYOSMART is a clinically proven solution for myopia management.^1-4 HOYA Vision Care has secured specific reimbursement for MiYOSMART myopia control spectacle lenses through inclusion in the List of Products and Services (LPP) code. To ensure as many priority children have access, this public coverage will also be further supported by complementary health insurance, depending on the parents’ responsible contract.

 “With more than 500,000 children in France set to be eligible to receive MiYOSMART spectacle lenses, this milestone is a hugely significant step forward for myopia management,” said Jean-Michel Lambert, General Manager of HOYA Vision Care France. “At HOYA Vision Care, we believe that ‘Every Child Deserves Better,’ and thanks to the dedication of the professionals and organizations who share this vision, we are proud to play our part in creating a healthier future, where every child has the opportunity to see clearly and unleash their full potential.”

 In France, approximately 510,000 children aged 6-15 experience severe myopia. That’s defined as having (≤ -6.00D), or annual progression of ≥ 0.50D.⁵

MiYOSMART is a spectacle lens based on the revolutionary Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. Backed by eight years of clinical follow-up data, MiYOSMART marks the longest-running clinical study on myopia management spectacle lenses. That trial found that wearing MiYOSMART spectacle lenses provide a continuous, long-term, effective, safe, non-invasive myopia control strategy in children.⁴

In a two-year randomized controlled clinical study, wearing MiYOSMART myopia control spectacle lenses slowed down myopia progression on average by 60%, compared to wearing standard single vision spectacle lenses.¹

“As a society, we need to take urgent action to mitigate the burden of myopia by making it a global priority for governments and public health bodies” said Prof. Dominique Bremond-Gignac. “The reimbursement of MiYOSMART in France is a significant step forward in our fight against childhood myopia. I hope this can signal a global movement, not only to acknowledge the need for prevention and early intervention, but also ensuring effective treatments are accessible to those who need them most— ensuring no child’s vision is irreversibly compromised.”

Additionally, since its launch in 2018, over 12 million MiYOSMART spectacle lenses have been purchased in over 40 countries worldwide.⁶